Vaccines Firm Goes to Vivalis in All-Share Deal Worth $175M
The French vaccines manufacturing technology company Vivalis SA is acquiring Austrian vaccines discoverer and developer Intercell AG, of Vienna, in an all-share deal valued at €133 million (US$175 million).